Prohibition extended on manufacturers interfering with access to 340B drugs.

HF 2703 extends Minnesota's prohibition on drug manufacturers interfering with access to 340B drugs by removing the law's previous expiration date of July 1, 2027. This means the restriction on manufacturers - preventing them from taking actions that limit access to discounted drugs - will remain in effect indefinitely. The law directly affects drug manufacturers by restricting certain business practices and benefits healthcare providers like hospitals and clinics that participate in the federal 340B program. These providers use 340B discounts to purchase drugs at lower prices for patients, particularly those with low incomes.